Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 4/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3781359 | 0.80 | RXFP1 (0.40) | HSD17B3ALDH1A1KDM4E | |
| SCHEMBL4583779 | 0.77 | HSD17B3 (0.58) | HSD17B3STSHTR7S1PR5KDM4E | |
| SCHEMBL21610337 | 0.77 | HSD17B3 (0.58) | HSD17B3STSHTR7S1PR5KDM4E | |
| SCHEMBL16429605 | 0.76 | ALDH1A1 (0.67) | HPGDALDH1A1MAOBKDM4E | |
| SCHEMBL15273098 | 0.76 | ALDH1A1 (0.67) | HPGDALDH1A1MAOBKDM4E | |
| SCHEMBL10008853 | 0.75 | HSD17B3 (0.57) | HSD17B3STSHTR7S1PR5KDM4E | |
| SCHEMBL11832428 | 0.75 | HPGD (0.42) | HSD17B3HPGDALDH1A1KDM4E | |
| SCHEMBL18270705 | 0.74 | CTSB (0.46) | HSD17B3HPGDALDH1A1 | |
| SCHEMBL15272906 | 0.74 | ALDH1A1 (0.68) | HPGDALDH1A1MAOBKDM4E | |
| SCHEMBL11801328 | 0.74 | CTNNB1 (0.41) | HPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | claimed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | claimed |
| US-20060154977-A1 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD, CORPORATION | 2006-07-13 | — | — | US | claimed |
| EP-1511736-A4 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2006-06-07 | — | — | EP | claimed |
| EP-1511736-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | Cortical Pty Ltd (AU) | 2005-03-09 | — | — | EP | claimed |
| WO-2003104203-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | claimed |
| EP-2319838-A1 | Therapeutic Molecules and Methods-1 | Cortical Pty Ltd (AU) | 2011-05-11 | — | — | EP | disclosed |
| EP-2319838-A1 | Therapeutic Molecules and Methods-1 | Cortical Pty Ltd (AU) | 2011-05-11 | — | — | EP | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
| US-20060154977-A1 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD, CORPORATION | 2006-07-13 | — | — | US | disclosed |
| EP-1511736-A4 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2006-06-07 | — | — | EP | disclosed |
| EP-1511736-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | Cortical Pty Ltd (AU) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003104203-A1 | THERAPEUTIC MOLECULES AND METHODS-1 | CORTICAL PTY LTD (AU) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154977-A1 | Therapeutic molecules and methods-1 | MIF, IL1B, IL1A | HSD17B3 838/4885HPGD 817/4885ALDH1A1 329/4885 |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MIF, IL1B, IL1A | HSD17B3 838/4885HPGD 817/4885ALDH1A1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.